Trending...
- Mission 3A Establishes Healthcare Advisory Board with Addition of Industry Leaders Patrick Fisher, Kevin Cordell, and Dr. Greg Berlet - 172
- InventHelp Inventor Develops New Therapeutic Aid (RSM-201) - 158
- SSATI Completes Acquisition of Invex Technology Solutions and ITIC Corporation's Government Support Services - 156
SAN DIEGO, May 7, 2025 ~ San Diego-based biotech firm, ViroMissile, has been recognized as the Top Cancer Destroying Platform 2025 by "Life Sciences Review" magazine. The company's pioneering approach to cancer treatment with its Intravenously Deliverable Oncolytic Virus (IDOV™) platform has caught the attention of the industry.
ViroMissile's innovative platform aims to provide a universal, single-dose therapy that can effectively target and eliminate various types of cancer. At the core of this breakthrough is a genetically engineered vaccinia virus that selectively infects and destroys cancer cells while simultaneously activating the body's immune response.
Unlike traditional oncolytic viruses that require direct tumor injections, ViroMissile's IDOV™ platform allows for systemic intravenous delivery. This means that the therapeutic virus can reach tumors throughout the body, making it a more efficient and less invasive treatment option.
More on The Californer
CEO of ViroMissile, Dr. Nanhai George Chen, explains their goal: "Our goal is to develop a broadly applicable therapy that leverages the immune system to combat cancer. By focusing on fundamental characteristics of cancer cells, such as rapid division, we aim to create a treatment effective across multiple cancer types."
Since its launch in 2018, ViroMissile has made significant progress in developing its third-generation oncolytic viruses. Pre-clinical studies in mouse models have shown promising results with a single injection being able to eradicate multiple cancers. Early clinical trials in China have also provided compelling evidence that the virus successfully reaches tumors in human patients. The company plans to conduct further clinical trials in the United States and Australia.
The IDOV™ platform includes several product candidates: IDOV-Safe™ for enhanced safety profiles, IDOV-Immune™ designed to boost immune system activation, IDOV-Stealth™ optimized for improved delivery by evading immune detection, and IDOV-Anti-Angio™ which targets tumor blood vessel formation to inhibit growth.
More on The Californer
ViroMissile's approach addresses a critical challenge in oncology - delivering effective therapies with minimal invasiveness and maximum efficiency. By enabling intravenous administration, the company hopes to overcome limitations associated with localized treatments and offer a more patient-friendly alternative.
The company's lean operational model, combined with strategic investments, has allowed for rapid progress without excessive overhead. This efficiency puts ViroMissile in a strong position to bring its innovative therapies to market swiftly and address unmet needs in cancer treatment.
As ViroMissile continues to advance its clinical programs, the company is actively seeking partnerships and investment to support further development and commercialization efforts. With its promising platform, ViroMissile is at the forefront of a new era in cancer therapy.
For more information on ViroMissile and its IDOV™ platform, please visit www.viromissile.com. Interested parties can also contact Derek Danziger, APR at 619-200-2145 for further inquiries.
ViroMissile's innovative platform aims to provide a universal, single-dose therapy that can effectively target and eliminate various types of cancer. At the core of this breakthrough is a genetically engineered vaccinia virus that selectively infects and destroys cancer cells while simultaneously activating the body's immune response.
Unlike traditional oncolytic viruses that require direct tumor injections, ViroMissile's IDOV™ platform allows for systemic intravenous delivery. This means that the therapeutic virus can reach tumors throughout the body, making it a more efficient and less invasive treatment option.
More on The Californer
- Long Beach to Commemorate its Naval History with Commemorative Community Event
- Long Beach: City Celebrates Inaugural National Home Improvement Month: Love Where You Live
- California sues Trump administration for illegally withholding billions in bipartisan infrastructure funds: 'Another Trump gift to China'
- Tale of two trains: California high-speed rail leaves Texas in the dust
- California: State invests nearly $33 billion in cap-and-trade dollars to make communities cleaner and healthier
CEO of ViroMissile, Dr. Nanhai George Chen, explains their goal: "Our goal is to develop a broadly applicable therapy that leverages the immune system to combat cancer. By focusing on fundamental characteristics of cancer cells, such as rapid division, we aim to create a treatment effective across multiple cancer types."
Since its launch in 2018, ViroMissile has made significant progress in developing its third-generation oncolytic viruses. Pre-clinical studies in mouse models have shown promising results with a single injection being able to eradicate multiple cancers. Early clinical trials in China have also provided compelling evidence that the virus successfully reaches tumors in human patients. The company plans to conduct further clinical trials in the United States and Australia.
The IDOV™ platform includes several product candidates: IDOV-Safe™ for enhanced safety profiles, IDOV-Immune™ designed to boost immune system activation, IDOV-Stealth™ optimized for improved delivery by evading immune detection, and IDOV-Anti-Angio™ which targets tumor blood vessel formation to inhibit growth.
More on The Californer
- Where AI Falls Short, Real Connections Rise—Media Outreach with Heart
- Cybersecurity is Protecting Your Personal Information and Your Portfolio
- EY US unveils Puneet Nanda of GuruNanda as an Entrepreneur Of The Year® 2025 Award Finalist
- California: Governor Newsom proclaims Children's Mental Health Awareness Week 2025
- VC Mastermind Launches: A Private Global Network and Podcast for Top-Tier Venture Capital Leaders
ViroMissile's approach addresses a critical challenge in oncology - delivering effective therapies with minimal invasiveness and maximum efficiency. By enabling intravenous administration, the company hopes to overcome limitations associated with localized treatments and offer a more patient-friendly alternative.
The company's lean operational model, combined with strategic investments, has allowed for rapid progress without excessive overhead. This efficiency puts ViroMissile in a strong position to bring its innovative therapies to market swiftly and address unmet needs in cancer treatment.
As ViroMissile continues to advance its clinical programs, the company is actively seeking partnerships and investment to support further development and commercialization efforts. With its promising platform, ViroMissile is at the forefront of a new era in cancer therapy.
For more information on ViroMissile and its IDOV™ platform, please visit www.viromissile.com. Interested parties can also contact Derek Danziger, APR at 619-200-2145 for further inquiries.
Filed Under: Business
0 Comments
Latest on The Californer
- California: Governor Newsom announces appointments 5.6.25
- Governor Newsom recognizes fallen California Highway Patrol officers
- California: Hear it from locals: State investment helps prevent and prosecute organized retail crime
- Long Beach Officials Honor the Fallen at Annual Police and Fire Memorial Ceremony
- SEEAG's Free "Farm Day Every Day" At Rincon Farms – May 31
- Elevate Capital Portfolio Company TrueLark Acquired by Weave Communications
- California: Governor Newsom proclaims Wildfire Preparedness Week 2025
- ABM for Good™ Launches First Project with Build Change
- 101334 Ltd. Acquires d4rkw3b, a Specialist Ad Network for Deep‑Web and High‑Risk Advertisers
- Red Lobster Announces Winners of National Ocean Sustainability Challenge
- Long Beach Parks, Recreation and Marine to Host Summer Kickoff Concert at El Dorado Park West on May 23
- ImagineX, in Collaboration with Qualys, Launches New mROC Services to Transform Enterprise Cyber Risk Management
- Ditch Micromanagement: New Leadership Book for Results-Driven, Accountability-Based Teams
- Jay Tapp was named Managing Director in British Columbia
- AliveCor Launches AI-Powered KardiaMobile 6L Max and KardiaAlert to Deliver the Most Advanced Personal ECG Solution on the Market
- Besides Health Insurance, What Insurance Do Freelancers Need?
- OhMyPretty Kinky Straight Half Wig: Perfect For Journeys
- Hubei Heavy Equipment Makes a Striking Appearance at CIMT and Competes with International Brands
- 20 Patents Issued Worldwide, Cementing Company Leadership. First Ever Cable-Free 12-Lead ECG: HeartBeam, Inc. (Stock Symbol: BEAT)
- NASDAQ Uplisting for Higher Market Exposure and Wide Corporate Benefits to AI Boosted Marketing Company On Track Towards $1 Billion Revenue by 2027